SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors.

Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

Five years after the World Health Organization declared a global pandemic, there has been progress — and backsliding in the ...

When the COVID-19 pandemic first began, we saw how quickly the SARS-CoV-2 virus evolved. New variants emerged with mutations ...

Today in BMC Medicine, researchers in Catalonia, Spain, estimate that 23% of adult COVID-19 survivors develop long COVID, ...

According to a study of the COVICAT cohort, almost one in four people infected with SARS-CoV-2 suffered from long-COVID. Long ...

That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...

The virus that causes COVID-19 continues to mutate. Scientists say that's likely to continue indefinitely, and the virus will ...

A Stanford-led team has found two antibodies that can work together to defeat all SARS-CoV-2 variants. More research is needed, but the approach could help in the development of treatments to keep ...

A team has found two antibodies that can work together to neutralize the virus that causes COVID-19 in all its current known variations in a laboratory environment. More research is needed, but the ...

The following is a summary of “Association between SARS-CoV-2 and stroke: perspectives from a metaumbrella-review,” published ...

March 05, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA™ (pemivibart) against the currently ...